Close Menu

Cancer

The latest news on cancer diagnostics, liquid biopsy, and cancer risk testing.

The company claims that mRNA-engineered CAR T cells don't cause the same toxicities as DNA-engineered cell therapies, making them suitable for frontline treatment.

During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.

The CHMP opinion is based on data from a Phase I/II study of dostarlimab in mismatch repair-deficient or microsatellite instability-high endometrial cancer.

Novartis plans to develop tislelizumab in combination with other agents in its pipeline and will commercialize the drug if it garners approval in these regions.

Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
23
Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
25
Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

Apr
08
Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.